Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Condition: Breast Neoplasm Female · Sponsor: Borstkanker Onderzoek Groep
About this study
Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence of an aromatase inhibitor in first line followed by fulvestrant plus CDK4/6 in second line.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (72)
| Jeroen Bosch Ziekenhuis | 's-Hertogenbosch, Netherlands | — |
| Noordwestziekenhuisgroep | Alkmaar, Netherlands | — |
| ZGT | Almelo, Netherlands | — |
| Flevoziekenhuis | Almere Stad, Netherlands | — |
| Meander Medisch Centrum | Amersfoort, Netherlands | — |
| Ziekenhuis Amstelland | Amstelveen, Netherlands | — |
| Nki - Avl | Amsterdam, Netherlands | — |
| VUmc | Amsterdam, Netherlands | — |
| AMC | Amsterdam, Netherlands | — |
| BovenIJ Ziekenhuis | Amsterdam, Netherlands | — |
| OLVG | Amsterdam, Netherlands | — |
| Gelre ziekenhuizen | Apeldoorn, Netherlands | — |
+ 60 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03425838